MEDIGARD INJECTS INTO THE US

Written on the 10 June 2010

MEDIGARD INJECTS INTO THE US

LISTED medical technology company Medigard (MGZ) has cracked the US market after signing a manufacturing and distribution deal for its innovative blood collection device (BCD).

The deal with distributor Outcome Solutions and an undisclosed manufacturer, is expected to create revenue streams within 18 months and could potentially be worth AUD$48 million annually within five years.

The initial agreement is to supply a minimum 10 per cent of 700 million BCD’s consumed by the US market per year. Four other Medigard products will also be put into production under the agreement.

CEO Peter Emery says the company chose the US over Asian export markets to ensure the quality of the products is maintained.

“Through selecting the right manufacturer, we will be able to deliver a price competitive product that is also of the highest quality, which will be of key importance to our success in the US market,” he says.

“These two key agreements we have been working towards for some time and are the culmination of months of negotiation, personal visits and the necessity of building key relationships.

“Both of our partners are commercially savvy and experienced operators and we look forward to working with them not only on the BCD, but also in development and production of our pipeline of products starting next with our 3mL syringe.”

Medigard got the medical sector excited last year when it announced the BCD and its retractable syringe, but share prices dropped 35 per cent since December 2009 when the company struggled to move from product development to commercialisation.

The Main Beach-based company suspended trading on Tuesday before announcing the agreement to the stock exchange last night.

Both agreements offer a three-way arrangement, with the manufacturer supplying the BCD direct to the distributor and Medigard receiving a royalty payment in the form of a licensing fee as its income of up to AUD 18c per device.

The company will now undertake a capital raising campaign to support the agreements and its expansion into the US.

“We expect to make an announcement in regard to an additional capital raising in the coming weeks. This is an exciting phase for Medigard and it provides the company with a clear path to getting the products on to the market,” says Emery.

MGZ shares last traded at 12c.


Latest News

STAFF CHURN BLAMED FOR MCGRATH EARNINGS DOWNGRADE

MCGRATH will fail to meet earnings forecasts after some of its star real estate agents defected to growing Perth firm...

MCBAIN RESIGNS AS BELLAMY'S DIRECTOR WHILE THIRD CLASS ACTION MOVES CLOSER TO SECURING FUNDING

LAURA McBain (pictured) has resigned as a director of Bellamy's Organic (ASX: BAL) today, effective immediatel...

REDBUBBLE TO MISS IPO FORECASTS

REDBUBBLE, the online marketplace for independent artists, will miss a series of forecasts set out in its IPO in its ...

BLUESCOPE CONTINUES STRONG RUN WITH GUIDANCE UPGRADE

BLUESCOPE Steel (ASX: BSL) is trading up 7.51 per cent at $11.16 per share after upgrading its half-year guidance thi...

Related News

CARSALES CEO RETIRES AS NEW COMPETITOR COX FINALISES MERGER

CARSALES will have a new CEO as it takes on a fresh challenger to its crown as the dominant online car sales portal i...

BUSINESS CONFIDENCE AT A SIX-YEAR HIGH

SMALL and medium businesses have entered 2017 with their confidence at a six-year high, building on strong gains m...

CONSUMERS PESSIMISTIC ENTERING 2017

CONSUMER confidence remains at its weakest point since April 2016, according to the latest Westpac Melbourne Institut...

RISE OF STARTUP SUPPORT PROGRAMS NOT AS ROSY AT IT SEEMS

ENTREPRENEURIAL cultivation companies in Australia are appearing quickly, but questions have been raised about whe...

Contact us

Email News Update Sign Up Contact Details
Subscriptions

PO Box 2087
Brisbane QLD 4001

LoginTell a FriendSign Up to Newsletter